SS-31 calculator
A mitochondria-targeted peptide studied in human trials for mitochondrial and heart disease. Investigational, with mixed trial results.
Also known as: Elamipretide, Bendavia, MTP-131
FDA status — not an approved drug Not FDA-approved for any use. SS-31 (elamipretide) is an investigational drug that has been through human clinical trials but has not been approved.
This draw does not fit the selected syringe.160 units exceeds the 100-unit barrel. Choose a larger syringe, use less bacteriostatic water, or split the dose.
Schedule SS-31 → Set your dosing schedule and get a phone notification when each dose is due. Free.
What SS-31 is
SS-31 (elamipretide) is a small mitochondria-targeted peptide that has been through actual human clinical trials — more than most compounds on this list. It was studied for primary mitochondrial myopathy, heart failure, and age-related conditions, with mixed results, and remains investigational.
Research depth: 3/5 Multiple human clinical trials completed — more than most here — though efficacy was mixed and it is not approved. Human trials: Phase 2/3 trials. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How SS-31 works
It selectively concentrates in the inner mitochondrial membrane and binds cardiolipin, a lipid essential for organizing the electron transport chain. By stabilizing cardiolipin, it is intended to improve mitochondrial energy production and reduce damaging oxidative byproducts in tissues with high energy demand.
SS-31 side effects
Commonly reported
- Injection-site reactions
- Generally well tolerated in trials
- Headache and dizziness reported
Serious — seek medical care
- Trial results were mixed — efficacy for its lead indications was not clearly established
- Long-term safety not yet established
- Investigational — not approved
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 50 mg vial reconstituted with 2 mL of bacteriostatic water gives 25 mg/mL. A 40000 mcg dose is then 1.6 mL — about 160 units on a 100-unit insulin syringe, giving roughly 1 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable SS-31 dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for SS-31 run from 40000 mcg to 80000 mcg. Figures reflect published trial dosing, which used daily subcutaneous amounts. This is investigational data, not a prescribing guide.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use SS-31 at all are decisions for a licensed clinician who knows your history.
Common questions
Has SS-31 been tested in humans?
Yes. Elamipretide has been through multiple human clinical trials, including in mitochondrial myopathy and heart failure, though results have been mixed and it is not approved.
What does SS-31 target?
It concentrates in mitochondria and binds cardiolipin, a lipid in the inner mitochondrial membrane, to stabilize the energy-producing machinery.